The estimated Net Worth of Michael Nally is at least $526 Thousand dollars as of 30 October 2019. Mr. Nally owns over 2,287 units of Merck & Co stock worth over $526,203 and over the last few years he sold MRK stock worth over $0. In addition, he makes $0 as Executive Vice President and Chief Marketing Officer at Merck & Co.
Mr. Nally MRK stock SEC Form 4 insider trading
Michael has made over 3 trades of the Merck & Co stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 2,287 units of MRK stock worth $194,258 on 30 October 2019.
The largest trade he’s ever made was exercising 2,287 units of Merck & Co stock on 30 October 2019 worth over $194,258. On average, Michael trades about 1,349 units every 45 days since 2019. As of 30 October 2019 he still owns at least 6,195 units of Merck & Co stock.
You can see the complete history of Mr. Nally stock trades at the bottom of the page.
Michael Nally biography
Michael Nally is appointed as Executive Vice President, Chief Marketing Officer of the Company with effective effective from January 1, 2019. Mr. Nally, most recently led the company’s Vaccines business. In his new role, Nally will report directly to Ken Frazier and will be a member of the Executive Committee. Nally will be responsible for Global Marketing and long-term franchise strategy across the portfolio. Nally has been at Merck since 2003 and served in a number of roles with responsibilities including being the Managing Director of UK, Ireland and Sweden as well a variety of roles in Commercial Operations, Business Development and Investor Relations.
How old is Michael Nally?
Michael Nally is 43, he’s been the Executive Vice President and Chief Marketing Officer of Merck & Co since 2019. There are 21 older and 1 younger executives at Merck & Co. The oldest executive at Merck & Co., Inc. is Thomas Cech, 72, who is the Independent Director.
What’s Michael Nally’s mailing address?
Michael’s mailing address filed with the SEC is MERCK & CO., INC., 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033.
Insider trading at Merck & Co
Over the last 10 years, insiders at Merck & Co have traded over $53,837,709 worth of Merck & Co stock and bought 47,800 units worth $1,519,400 . The most active insider traders include Wendell P Weeks, Kenneth C Frazier, and Adam H Schechter. On average, Merck & Co executives and independent directors trade stock every 15 days with the average trade being worth of $3,440,102. The most recent stock trade was executed by Steven Mizell on 30 October 2019, trading 4,574 units of MRK stock currently worth $379,276.
What does Merck & Co do?
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species, which it sells to veterinarians, distributors, and animal producers. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the Company’s relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
What does Merck & Co’s logo look like?
Complete history of Mr. Nally stock trades at Merck & Co
Merck & Co executives and stock owners
Merck & Co executives and other stock owners filed with the SEC include:
- Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer
- Roger Perlmutter, Executive Vice President, President – Merck Research Laboratories
- Robert Davis, Executive Vice President, Global Services, Chief Financial Officer
- Jennifer Zachary, Executive Vice President, General Counsel
- Peter Wendell, Independent Director
- Wendell Weeks, Independent Director
- Rochelle Lazarus, Independent Director
- Leslie Brun, Lead Independent Director
- Paul Rothman, Independent Director
- Pamela Craig, Independent Director
- Thomas Cech, Independent Director
- Patricia Russo, Independent Director
- Thomas Glocer, Independent Director
- Inge Thulin, Independent Director
- Mary Coe, Independent Director
- Rita Karachun, Senior Vice President Finance – Global Controller
- Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health
- Richard DeLuca, Executive Vice President, President – Merck Animal Health
- Frank Clyburn, Executive Vice President, Chief Commercial Officer
- Sanat Chattopadhyay, Executive Vice President and President – Merck Manufacturing Division
- Michael Nally, Executive Vice President, Chief Marketing Officer
- Jim Scholefield, Executive Vice President, Chief Information and Digital Officer
- Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources
- Craig B. Thompson, Director
- Adam H Schechter, EVP & Pres-Global Human Health
- Adele D Ambrose, V-P & Chief Com. Officer
- Clark Golestani, EVP & Chief Info Officer
- John H Noseworthy, Director
- Michael J Holston, EVP, Chief Ethics & Compl Ofcr
- Carlos E Represas, Director
- C Robert Kidder, Director
- Weir Mirian M Graddick, Exec. V-P, Human Resources
- Ashley Watson, SVP Chief Ethics & Com Officer
- James H Scholefield, EVP,Chief Info&Digital Officer
- Michael Fleming, SVP Chief Ethics & Com Officer
- William B Jr Harrison, Director
- Michael Rosenblatt, Exec V-P & Chief Med Officer
- John Canan, Senior V-P, Controller
- Stanley F Barshay, Exec V-P Consumer Health Care
- Willie A Deese, Exec. V-P and Pres., MMD
- Anne M Tatlock, Director
- Samuel O Md Thier, Director
- Mervyn Turner, Chief Strategy Officer
- Willam N Kelley, Director
- Richard S Iii Bowles, Exe V-P & Chief Compl Officer
- Peter S Kim, Exec. V-P and Pres., MRL
- Thomas E Shenk, Director
- Bridgette P Heller, Exe.VP & Pres.Con.Hlth.Care
- Raul E Kohan, Exe V-P & Pres, Animal Health
- Steven F Goldstone, Director
- Harry R Jacobson, Director
- Richard T Clark, Chairman, President and CEO
- Peter N Kellogg, Exec. V.P. & C.F.O
- Bruce N Kuhlik, Exec. V.P. and General Counsel
- Cuong V Do, EVP & Chief Strategy Officer
- J Chris Scalet, Exe. VP, Global Services & CIO
